Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher's Ion PGM Dx System Receives CE-IVD Mark

NEW YORK (GenomeWeb) – Thermo Fisher Scientific today said that its Ion PGM Dx System has been CE-IVD marked for sale in Europe.

The system was developed using Ion Torrent next-generation sequencing technology and was validated using "challenging" germline variants with library kits based on the Ion AmpliSeq technology. The Ion PGM Dx System includes the instrument, GMP reagents, and software controls to establish high-performing next-generation clinical sequencing workflows, Thermo Fisher said.

The company is accepting orders for the platform in Europe and plans to begin fulfilling them later this year.

CE-IVD registration of the system will allow clinical laboratories in Europe to more easily develop and implement NGS-based diagnostic assays in accordance with the European Directive on In Vitro Diagnostic Medical Devices, Mark Stevenson, president of Life Sciences Solutions at Thermo Fisher, said in a statement. The system provides accurate genetic variant analysis using as little as 10 ng of sample DNA and provides the rapid turnaround time needed in a clinical setting, he added.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.